Michael Thurn

Michael Thurn is an experienced executive in the pharmaceutical and biotechnology sectors, currently serving as Managing Director and Chief Executive Officer at Neurizon since May 2024 and as Co-Founder & Director at MARP Therapeutics Pty Ltd since December 2021. Previously, Michael held leadership positions including Chief Executive Officer at PharmAust Ltd from September 2023 to April 2024, and Chief Executive Officer at Mimetica Pty Limited from September 2006 to November 2021. Additional roles include Chief Operating Officer at Botanix Pharmaceuticals and Cytopia Research Pty Ltd, as well as Head of Drug Development at Xenome Limited. Early career experience includes important positions such as Senior Toxicologist at TGA and Anti-cancer Program Team Leader at Novogen. Michael holds a Doctor of Philosophy (Ph.D.) from the University of Technology Sydney.